Vericel Corporation (VCEL) SEC Filings & Earnings Calls

Gross margin slightly declined from 74% to 73% due to product mix; potential for further margin pressure if mix shifts.

“Gross profit for the quarter ended June 30, 2026 was $56.4 million, or 73% of net revenue, compared to $46.6 million, or 74% of net revenue, for the second quarter of 2025.” · word for word

Operating expenses increased due to headcount and marketing; could pressure profitability if revenue growth slows.

“Total operating expenses for the quarter ended June 30, 2026 were $56.0 million, compared to $48.6 million for the same period in 2025. The increase in operating expenses was primarily due to increased headcount and related employee expenses, including the MACI sales force expansion, and an increase in marketing programs.” · word for word

Supply chain disruption for NexoBrid

“Certain raw materials utilized in NexoBrid’s manufacture, including the supply of the active ingredient bromelain, are sourced from Taiwan.” · word for word

Geopolitical risk from Israel manufacturing

“The manufacturing process for NexoBrid is conducted by MediWound, primarily at manufacturing locations in Israel.” · word for word

Dependence on single-source suppliers

“We hold exclusive license and supply agreements with MediWound to commercialize NexoBrid in North America.” · word for word

Geopolitical risks from Middle East conflicts could impact NexoBrid supply from MediWound in Israel.

“Conflicts in the Middle East region involving Israel or those related to disruptions of land or sea transportation routes or distribution or shipping channels.” · word for word

Manufacturing scale-up risk for cell therapy products at new facility.

“The ability to continue to scale our manufacturing operations to meet the demand for our cell therapy products.” · word for word

NexoBrid revenue decline and supply chain risk

“NexoBrid $1,142 and $1,337 for the three months ended March 31, 2026 and 2025, respectively.”

Operating losses persist

“Loss from operations $(8,064) and $(12,792) for the three months ended March 31, 2026 and 2025, respectively.”

Dependence on FDA approvals for growth

“MACI Arthro and potential ankle indication are key growth drivers; any regulatory setback could impact growth.”

Revenue concentration on MACI

“MACI revenue of $239.5 million represents 87% of total revenue”

Dependence on FDA approvals for growth initiatives

“MACI Ankle approval and international expansion depend on regulatory approvals”

Manufacturing scale-up risk

“the ability to continue to scale our manufacturing operations to meet the demand for our cell therapy products, including the timely qualification of a new manufacturing facility in Burlington, Massachusetts” · word for word

Supply chain concentration risk

“Certain raw materials utilized in NexoBrid's manufacture, including the supply of the active ingredient bromelain, are sourced from Taiwan.” · word for word

Geopolitical risk (Israel)

“The manufacturing process for NexoBrid is conducted by MediWound, primarily at manufacturing locations in Israel.” · word for word

Patent expiration risk

“When these patents and data exclusivity expire, our opportunity to establish or maintain product revenue could be substantially reduced.” · word for word

Concentration risk on MACI product (87% of revenue); any competitive or regulatory setback could materially impact results.

“MACI net revenue of $239.5 million out of $276.3 million total revenue”

Manufacturing transition to new Burlington facility introduces execution risk; delays could affect supply.

“Remain on track to begin MACI commercial manufacturing in new facility in 2026” · word for word

Regulatory approval for MACI in the UK (MHRA) is pending; failure or delay could limit international expansion.

“On track to submit MACI marketing authorization application to U.K. MHRA in 2026” · word for word

Middle East supply disruption

“To the extent conflicts in the Middle East region were to result in damage to MediWound’s facilities in Israel or inhibit travel or commercial shipments to and from Israel, MediWound’s ability to continue to supply NexoBrid to the U.S. market could be disrupted.” · word for word

FDA regulatory disruption

“Disruptions at the FDA and other agencies may also slow the time necessary to review and/or approve product candidates or changes to existing products, approve the qualification of the Burlington manufacturing facility and/or conduct required inspections of our and/or third-party manufacturing and testing facilities” · word for word

Operating expenses increased due to headcount and new facility costs.

“increase in operating expenses was primarily due to increased headcount and related employee expenses and additional costs related to the Company’s new Burlington facility” · word for word